Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2003 Dec;74(12):1615–1620. doi: 10.1136/jnnp.74.12.1615

Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke

Z Szolnoki 1, F Somogyvari 1, A Kondacs 1, M Szabo 1, L Fodor 1, J Bene 1, B Melegh 1
PMCID: PMC1757435  PMID: 14638877

Abstract

Objectives: Ischaemic stroke is a frequent heterogeneous multifactorial disease that is affected by a number of genetic mutations and environmental factors. We hypothesised the clinical importance of the interactions between common, unfavourable genetic mutations and clinical risk factors in the development of ischaemic stroke.

Methods: The Factor V Leiden G1691A (Leiden V), the prothrombin G20210A, the methylenetetrahydrofolate reductase C677T (MTHFR C677T) mutations, the angiotensin converting enzyme I/D (ACE I/D), and apolipoprotein allele e4 (APO e4) genotypes were examined by the polymerase chain reaction (PCR) technique in 867 ischaemic stroke patients and 743 healthy controls. Logistic regression models were used to estimate the roles of the co-occurrences of the clinical risk factors and common genetic mutations in ischaemic stroke.

Results: The Leiden V mutation in combination with hypertension or diabetes mellitus increased the risk of ischaemic stroke. We found synergistic effects between the ACE D/D and MTHFR 677TT genotypes and drinking or smoking. The presence of the APO e4 greatly facilitated the unfavourable effects of hypertension, diabetes mellitus, smoking, or drinking on the incidence of ischaemic stroke.

Conclusion: In certain combinations, pairing of common unfavourable genetic factors, which alone confer only minor or non-significant risk, with clinical risk factors can greatly increase the susceptibility to ischaemic stroke.

Full Text

The Full Text of this article is available as a PDF (315.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agerholm-Larsen B., Tybjaerg-Hansen A., Frikke-Schmidt R., Grønholdt M. L., Jensen G., Nordestgaard B. G. ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease. Ann Intern Med. 1997 Sep 1;127(5):346–355. doi: 10.7326/0003-4819-127-5-199709010-00002. [DOI] [PubMed] [Google Scholar]
  2. Appleby R. D., Olds R. J. The inherited basis of venous thrombosis. Pathology. 1997 Nov;29(4):341–347. doi: 10.1080/00313029700169285. [DOI] [PubMed] [Google Scholar]
  3. Catto A., Carter A., Ireland H., Bayston T. A., Philippou H., Barrett J., Lane D. A., Grant P. J. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995 Jun;15(6):783–785. doi: 10.1161/01.atv.15.6.783. [DOI] [PubMed] [Google Scholar]
  4. Chaturvedi S., Dzieczkowski J. S. Protein S deficiency, activated protein C resistance and sticky platelet syndrome in a young woman with bilateral strokes. Cerebrovasc Dis. 1999 Mar-Apr;9(2):127–130. doi: 10.1159/000015911. [DOI] [PubMed] [Google Scholar]
  5. Chowdhury A. H., Yokoyama T., Kokubo Y., Zaman M. M., Haque A., Tanaka H. Apolipoprotein E genetic polymorphism and stroke subtypes in a Bangladeshi hospital-based study. J Epidemiol. 2001 May;11(3):131–138. doi: 10.2188/jea.11.131. [DOI] [PubMed] [Google Scholar]
  6. Clark Z. E., Bowen D. J., Whatley S. D., Bellamy M. F., Collins P. W., McDowell I. F. Genotyping method for methylenetetrahydrofolate reductase (C677T thermolabile variant) using heteroduplex technology. Clin Chem. 1998 Nov;44(11):2360–2362. [PubMed] [Google Scholar]
  7. Crook R., Hardy J., Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods. 1994 Aug;53(2):125–127. doi: 10.1016/0165-0270(94)90168-6. [DOI] [PubMed] [Google Scholar]
  8. Danneberg J., Abbes A. P., Bruggeman B. J., Engel H., Gerrits J., Martens A. Reliable genotyping of the G-20210-A mutation of coagulation factor II (prothrombin). Clin Chem. 1998 Feb;44(2):349–351. [PubMed] [Google Scholar]
  9. De Lucia D., Papa M. L., Ammendola F., Pezzella S., Del Giudice V., Marotta R., Renis V., Di Mauro C., Maisto G., Masi S. Association of elevated levels of prothrombin fragment 1+2 and Arg506 to Gln mutation in patients with a history of ischemic stroke. J Neurosurg Sci. 1999 Mar;43(1):45–51. [PubMed] [Google Scholar]
  10. De Stefano V., Chiusolo P., Paciaroni K., Casorelli I., Rossi E., Molinari M., Servidei S., Tonali P. A., Leone G. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood. 1998 May 15;91(10):3562–3565. [PubMed] [Google Scholar]
  11. Doi Y., Yoshinari M., Yoshizumi H., Ibayashi S., Wakisaka M., Fujishima M. Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction. Atherosclerosis. 1997 Jul 25;132(2):145–150. doi: 10.1016/s0021-9150(97)00080-4. [DOI] [PubMed] [Google Scholar]
  12. Elbaz A., Amarenco P. Genetic susceptibility and ischaemic stroke. Curr Opin Neurol. 1999 Feb;12(1):47–55. doi: 10.1097/00019052-199902000-00009. [DOI] [PubMed] [Google Scholar]
  13. Eskandari M. K., Bontempo F. A., Hassett A. C., Faruki H., Makaroun M. S. Arterial thromboembolic events in patients with the factor V Leiden mutation. Am J Surg. 1998 Aug;176(2):122–125. doi: 10.1016/s0002-9610(98)00161-5. [DOI] [PubMed] [Google Scholar]
  14. Frisoni G. B., Calabresi L., Geroldi C., Bianchetti A., D'Acquarica A. L., Govoni S., Sirtori C. R., Trabucchi M., Franceschini G. Apolipoprotein E epsilon 4 allele in Alzheimer's disease and vascular dementia. Dementia. 1994 Sep-Oct;5(5):240–242. doi: 10.1159/000106730. [DOI] [PubMed] [Google Scholar]
  15. Gaustadnes M., Rüdiger N., Møller J., Rasmussen K., Bjerregaard Larsen T., Ingerslev J. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinolysis. 1999 Jul;10(5):251–259. doi: 10.1097/00001721-199907000-00006. [DOI] [PubMed] [Google Scholar]
  16. Glueck C. J., Fontaine R. N., Wang P. Interaction of heritable and estrogen-induced thrombophilia: possible etiologies for ischemic optic neuropathy and ischemic stroke. Thromb Haemost. 2001 Feb;85(2):256–259. [PubMed] [Google Scholar]
  17. Greengard J. S., Xu X., Gandrille S., Griffin J. H. Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln506-factor V. Thromb Res. 1995 Dec 1;80(5):441–443. doi: 10.1016/0049-3848(95)00197-y. [DOI] [PubMed] [Google Scholar]
  18. Harmon D. L., Doyle R. M., Meleady R., Doyle M., Shields D. C., Barry R., Coakley D., Graham I. M., Whitehead A. S. Genetic analysis of the thermolabile variant of 5, 10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol. 1999 Feb;19(2):208–211. doi: 10.1161/01.atv.19.2.208. [DOI] [PubMed] [Google Scholar]
  19. Hassan A., Markus H. S. Genetics and ischaemic stroke. Brain. 2000 Sep;123(Pt 9):1784–1812. doi: 10.1093/brain/123.9.1784. [DOI] [PubMed] [Google Scholar]
  20. Huisman M. V., Rosendaal F. Thrombophilia. Curr Opin Hematol. 1999 Sep;6(5):291–297. doi: 10.1097/00062752-199909000-00004. [DOI] [PubMed] [Google Scholar]
  21. Kontula K., Ylikorkala A., Miettinen H., Vuorio A., Kauppinen-Mäkelin R., Hämäläinen L., Palomäki H., Kaste M. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost. 1995 Apr;73(4):558–560. [PubMed] [Google Scholar]
  22. Kostulas K., Huang W. X., Crisby M., Jin Y. P., He B., Lannfelt L., Eggertsen G., Kostulas V., Hillert J. An angiotensin-converting enzyme gene polymorphism suggests a genetic distinction between ischaemic stroke and carotid stenosis. Eur J Clin Invest. 1999 Jun;29(6):478–483. doi: 10.1046/j.1365-2362.1999.00476.x. [DOI] [PubMed] [Google Scholar]
  23. Lalouschek W., Aull S., Serles W., Schnider P., Mannhalter C., Pabinger-Fasching I., Deecke L., Zeiler K. C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. Thromb Res. 1999 Jan 15;93(2):61–69. doi: 10.1016/s0049-3848(98)00154-6. [DOI] [PubMed] [Google Scholar]
  24. Longstreth W. T., Jr, Rosendaal F. R., Siscovick D. S., Vos H. L., Schwartz S. M., Psaty B. M., Raghunathan T. E., Koepsell T. D., Reitsma P. H. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) Stroke. 1998 Mar;29(3):577–580. doi: 10.1161/01.str.29.3.577. [DOI] [PubMed] [Google Scholar]
  25. Lüdemann P., Nabavi D. G., Junker R., Wolff E., Papke K., Buchner H., Assmann G., Ringelstein E. B. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients. Stroke. 1998 Dec;29(12):2507–2510. doi: 10.1161/01.str.29.12.2507. [DOI] [PubMed] [Google Scholar]
  26. MacLeod M. J., De Lange R. P., Breen G., Meiklejohn D., Lemmon H., Clair D. S. Lack of association between apolipoprotein E genoype and ischaemic stroke in a Scottish population. Eur J Clin Invest. 2001 Jul;31(7):570–573. doi: 10.1046/j.1365-2362.2001.00851.x. [DOI] [PubMed] [Google Scholar]
  27. Markus H. S., Barley J., Lunt R., Bland J. M., Jeffery S., Carter N. D., Brown M. M. Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma. Stroke. 1995 Aug;26(8):1329–1333. doi: 10.1161/01.str.26.8.1329. [DOI] [PubMed] [Google Scholar]
  28. McColl M. D., Chalmers E. A., Thomas A., Sproul A., Healey C., Rafferty I., McWilliam R., Eunson P. Factor V Leiden, prothrombin 20210G-->A and the MTHFR C677T mutations in childhood stroke. Thromb Haemost. 1999 May;81(5):690–694. [PubMed] [Google Scholar]
  29. Meschia J. F., Biller J., Witt T., Greist A., Rhinehart S. N. Is hormone replacement a risk factor for ischemic stroke in women with factor V Leiden mutation? Arch Neurol. 1998 Aug;55(8):1137–1139. doi: 10.1001/archneur.55.8.1137. [DOI] [PubMed] [Google Scholar]
  30. Nabavi D. G., Junker R., Wolff E., Lüdemann P., Doherty C., Evers S., Droste D. W., Kessler C., Assmann G., Ringelstein E. B. Prevalence of factor V Leiden mutation in young adults with cerebral ischaemia: a case-control study on 225 patients. J Neurol. 1998 Oct;245(10):653–658. doi: 10.1007/s004150050262. [DOI] [PubMed] [Google Scholar]
  31. Nakata Y., Katsuya T., Takami S., Sato N., Fu Y., Ishikawa K., Takiuchi S., Rakugi H., Miki T., Higaki J. Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. Am J Hypertens. 1998 Aug;11(8 Pt 1):1019–1023. doi: 10.1016/s0895-7061(98)00046-6. [DOI] [PubMed] [Google Scholar]
  32. Notsu Y., Nabika T., Park H. Y., Masuda J., Kobayashi S. Evaluation of genetic risk factors for silent brain infarction. Stroke. 1999 Sep;30(9):1881–1886. doi: 10.1161/01.str.30.9.1881. [DOI] [PubMed] [Google Scholar]
  33. Orlandi G., Pellegrinetti A., Fioretti C., Martini A., Murri L. Factor V Leiden mutation in a case with ischemic stroke: which relationship? A case report. Angiology. 1998 Jan;49(1):79–82. doi: 10.1177/000331979804900111. [DOI] [PubMed] [Google Scholar]
  34. Pedro-Botet J., Sentí M., Rubiés-Prat J. Apolipoprotein E polymorphism and ischemic cerebrovascular disease. Stroke. 1994 Feb;25(2):521–521. [PubMed] [Google Scholar]
  35. Press R. D., Beamer N., Evans A., DeLoughery T. G., Coull B. M. Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke. Diagn Mol Pathol. 1999 Mar;8(1):54–58. doi: 10.1097/00019606-199903000-00009. [DOI] [PubMed] [Google Scholar]
  36. Rees D. C., Cox M., Clegg J. B. World distribution of factor V Leiden. Lancet. 1995 Oct 28;346(8983):1133–1134. doi: 10.1016/s0140-6736(95)91803-5. [DOI] [PubMed] [Google Scholar]
  37. Ridker P. M., Glynn R. J., Miletich J. P., Goldhaber S. Z., Stampfer M. J., Hennekens C. H. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997 Apr 1;126(7):528–531. doi: 10.7326/0003-4819-126-7-199704010-00005. [DOI] [PubMed] [Google Scholar]
  38. Ridker P. M., Hennekens C. H., Miletich J. P. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 1999 Mar 2;99(8):999–1004. doi: 10.1161/01.cir.99.8.999. [DOI] [PubMed] [Google Scholar]
  39. Salooja N., Catto A., Carter A., Tudenham E. G., Grant P. J. Methylene tetrahydrofolate reductase C677T genotype and stroke. Clin Lab Haematol. 1998 Dec;20(6):357–361. doi: 10.1046/j.1365-2257.1998.00158.x. [DOI] [PubMed] [Google Scholar]
  40. Somogyvári F., Szolnoki Z., Márki-Zay J., Fodor L. Real-time PCR assay with fluorescent hybridization probes for exact and rapid genotyping of the angiotensin-converting enzyme gene insertion/deletion polymorphism. Clin Chem. 2001 Sep;47(9):1728–1729. [PubMed] [Google Scholar]
  41. Stolz E., Kemkes-Matthes B., Pötzsch B., Hahn M., Kraus J., Wirbartz A., Kaps M. Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis. Acta Neurol Scand. 2000 Jul;102(1):31–36. doi: 10.1034/j.1600-0404.2000.102001031.x. [DOI] [PubMed] [Google Scholar]
  42. Szolnoki Z., Somogyvári F., Kondacs A., Szabó M., Fodor L. Evaluation of the roles of common genetic mutations in leukoaraiosis. Acta Neurol Scand. 2001 Nov;104(5):281–287. doi: 10.1034/j.1600-0404.2001.00355.x. [DOI] [PubMed] [Google Scholar]
  43. Szolnoki Z., Somogyvári F., Kondacs A., Szabó M., Fodor L. Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke. J Neurol. 2001 Sep;248(9):756–761. doi: 10.1007/s004150170090. [DOI] [PubMed] [Google Scholar]
  44. Szolnoki Z., Somogyvári F., Szabó M., Fodor L. A clustering of unfavourable common genetic mutations in stroke cases. Acta Neurol Scand. 2000 Aug;102(2):124–128. doi: 10.1034/j.1600-0404.2000.102002124.x. [DOI] [PubMed] [Google Scholar]
  45. Szolnoki Z., Somogyvári F., Szólics M., Szabó M., Fodor L. Common genetic mutations as possible aetiological factors in stroke. Eur Neurol. 2001;45(2):119–120. doi: 10.1159/000052105. [DOI] [PubMed] [Google Scholar]
  46. Takami S., Imai Y., Katsuya T., Ohkubo T., Tsuji I., Nagai K., Satoh H., Hisamichi S., Higaki J., Ogihara T. Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study. Am J Hypertens. 2000 Feb;13(2):121–127. doi: 10.1016/s0895-7061(99)00184-3. [DOI] [PubMed] [Google Scholar]
  47. Topić E., Simundić A. M., Ttefanović M., Demarin V., Vuković V., Lovrencić-Huzjan A., Zuntar I. Polymorphism of apoprotein E (APOE), methylenetetrahydrofolate reductase (MTHFR) and paraoxonase (PON1) genes in patients with cerebrovascular disease. Clin Chem Lab Med. 2001 Apr;39(4):346–350. doi: 10.1515/CCLM.2001.054. [DOI] [PubMed] [Google Scholar]
  48. Ueda S., Weir C. J., Inglis G. C., Murray G. D., Muir K. W., Lees K. R. Lack of association between angiotensin converting enzyme gene insertion/deletion polymorphism and stroke. J Hypertens. 1995 Dec;13(12 Pt 2):1597–1601. [PubMed] [Google Scholar]
  49. Weih M., Vetter B., Castell S., Ziemer S., Kulozik A. E., Einhäupl K. M. Hereditary thrombophilia in cerebral venous thrombosis. Cerebrovasc Dis. 2000 Mar-Apr;10(2):161–162. doi: 10.1159/000016049. [DOI] [PubMed] [Google Scholar]
  50. Zee R. Y., Ridker P. M., Stampfer M. J., Hennekens C. H., Lindpaintner K. Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. Circulation. 1999 Jan 26;99(3):340–343. doi: 10.1161/01.cir.99.3.340. [DOI] [PubMed] [Google Scholar]
  51. Zenz W., Bodó Z., Plotho J., Streif W., Male C., Bernert G., Rauter L., Ebetsberger G., Kaltenbrunner K., Kurnik P. Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. Thromb Haemost. 1998 Nov;80(5):763–766. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES